Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5508572 | 1.00 | SIRT2 (0.32) | SIRT2BACE1PPARGPPARAMDM2 | |
| SCHEMBL5508568 | 0.88 | BACE1 (0.31) | BACE1PPARGPPARAMDM2 | |
| Hydrochloric Acid SCHEMBL5502983 | 0.86 | PPARG (0.35) | SIRT2PPARGPPARAMDM2CASP3 | |
| SCHEMBL4432786 | 0.81 | BACE1 (0.38) | BACE1MDM2CASP3 | |
| SCHEMBL1998054 | 0.78 | MDM4 (0.46) | MDM2CASP3 | |
| SCHEMBL1998055 | 0.78 | MDM4 (0.46) | MDM2CASP3 | |
| SCHEMBL30229531 | 0.78 | MDM4 (0.46) | MDM2CASP3 | |
| SCHEMBL5502110 | 0.76 | PPARG (0.36) | PPARGPPARACASP3 | |
| Hydrochloric Acid SCHEMBL5502082 | 0.74 | PPARG (0.36) | PPARGPPARACASP3 | |
| SCHEMBL29633905 | 0.74 | FABP5 (0.37) | MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773877-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Bristol-Myers Squibb Company (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014287-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-09 | — | — | WO | disclosed |